Navigation Links
Ampio Provides Progress Report on Clinical Programs in Preparation for Annual Shareholders Meeting
Date:11/14/2012

re oxidative stress starts damaging important biological structures and molecules.
  • Ampio entered into a manufacturing contract with UHV (San Jose, CA) for the manufacture of the single-use disposable electrodes and the instrument/reader is in its final stages of development/assembly.
  • Multiple clinical studies have been completed (thousands of patients) encompassing the many potential indications for this platform technology and are awaiting final analysis and publication of results.  Ampio will focus the initial clinical indication to the best obtained results from these extensive clinical studies.
  • Ampio believes the ORP device will be cleared by the FDA under a 510(k).
  • Ampio anticipates spinning-off this program into a separately financed entity.
  • About Ampio
    Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for inflammation, eye disease, kidney disease, CNS disease, metabolic disease and male sexual dysfunction. The product pipeline includes new uses for previously approved drugs and new molecular entities ("NMEs"). By concentrating on development of new uses for previously approved drugs, approval timelines, costs and risk of clinical failure are reduced because these drugs have strong potential to be safe and effective while their shorter development times can significantly increase near term value. A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's product development programs. For more information about Ampio, please visit our website, www.ampiopharma.com.

    Forward-Looking Statements 
    Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of wor
    '/>"/>

    SOURCE Ampio Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Novation Champions Reusable Packaging for Sustainability in Healthcare
    2. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
    3. Champions Oncology Reports Financial Results for the Quarter Ended July 31, 2012
    4. Terso Solutions partners with Champion Medical Technologies to offer fully automated tracking of Tissue and Implantable Devices
    5. Champions Oncology to Present at Rodman & Renshaw Conference
    6. Champions Oncology Reports Resignation Of Director
    7. eCardio Supports the Carolinas HealthCare Foundation Through Grant for Heart Of A Champion Day
    8. Ampio Pharmaceuticals Announces Closing of Public Offering
    9. Ampio Advances NCE001 Cancer Drug into Preclinical Development Following Successful Recent Financing and the Granting of Patents in USA, Canada, Europe and China
    10. Ampio Pharmaceuticals Announces Exercise of Over-Allotment Option
    11. Ampio Pharmaceuticals Announces Pricing of Public Offering of 4,615,400 Shares of Common Stock
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2014)... July 31, 2014   , 2014 Second Quarter ... prior year , Overall organic growth was 4% for same ... products; Bausch + Lomb grew 12% , 2014 Second ... 43% , 2014 Second Quarter GAAP Operating Cash Flow ... , Highlights of the Second Quarter , Launched 17 new ...
    (Date:7/31/2014)... PARK, N.C. , July 31, 2014 ... Miami facilities to meet the clinical trial ... .  The newly expanded facility will continue to ... consolidation of shipments to and from the region, and ... its newest location, Marken will combine its office and ...
    (Date:7/31/2014)... , July 31, 2014 Auxilium ... a specialty biopharmaceutical company, today announced that the ... payment from its partner Asahi Kasei Pharma Corporation ... the successful submission of a regulatory application to ... for XIAFLEX ® (collagenase clostridium histolyticum) for ...
    Breaking Medicine Technology:Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 2Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 3Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 4Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 5Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 6Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 7Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 8Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 9Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 10Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 11Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 12Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 13Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 14Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 15Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 16Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 17Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 18Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 19Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 20Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 21Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 22Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 23Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 24Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 25Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 26Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 27Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 28Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 29Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 30Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 31Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 32Marken Expands Miami Regional Logistics Center 2Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 2Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 3Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 4
    ... , BUDAPEST, Hungary , ... Pfizer Globally Licenses ChemAxon,s Platform For Markush Structure,Searching And Enumeration ... of cheminformatics software for the life,sciences industry has entered into ... functionality for global,development and deployment within Pfizer,s global R&D facilities. ...
    ... , , , ... The U.S. Food and Drug Administration today approved Ampyra (dalfampridine) ... sclerosis (MS). In clinical trials, patients treated with Ampyra had ... (placebo). This is the first drug approved for this use. ...
    Cached Medicine Technology:FDA Approves Ampyra to Improve Walking in Adults with Multiple Sclerosis 2
    (Date:7/31/2014)... Some pain relief medications can be as addictive as heroin ... 46 people in the U.S. die from legal pain pills ... to an emergency room because of opioid complications. Consumer ... prescription and over-the-counter painkillers and is calling on the U.S. ... these drugs safer. , The full report, “Deadly Pain Pills” ...
    (Date:7/31/2014)... York, NY (PRWEB) July 31, 2014 ... IT solutions firm based in New York City, has ... infrastructure for the midtown Manhattan headquarters of a large ... corporate and investment banking. , Chico Ramnarayan, Chief Executive ... our client is an opportunity for us to further ...
    (Date:7/31/2014)... July 31, 2014 Sales in the organic ... to 2014, according to radio talk show host Sharon Kleyne, ... rapid growth since 1990. The US economy in the same ... Power of Water radio show, reported this information following a ... a worldwide manufacturer of organic and natural food products. ...
    (Date:7/31/2014)... 2014 Staying happy in a relationship and ... Men and women get sucked into the logistical ruts they ... taxi services to kids. , That’s why Couples in ... + Fun Ways to Reignite the Spark in Your Marriage ... “This is a much better path to happiness, and a ...
    (Date:7/31/2014)... 2014 Loffler Companies, the leading business ... recognized by Microsoft as a Microsoft Community Connections Partner ... on July 14, 2014. , The Microsoft U.S. ... that deliver cloud-based IT services and solutions to small ... an U.S. SMB Champions Club member, Loffler has established ...
    Breaking Medicine News(10 mins):Health News:Consumer Reports Warns Against the Risks of Prescription and Over-The-Counter Painkillers 2Health News:Consumer Reports Warns Against the Risks of Prescription and Over-The-Counter Painkillers 3Health News:Global Bank Awards CRA with Network Infrastructure Contract 2Health News:Organic Food Industry Grew 12% in 2013-2014 Reports Sharon Kleyne Hour Power of Water Host 2Health News:Organic Food Industry Grew 12% in 2013-2014 Reports Sharon Kleyne Hour Power of Water Host 3Health News:Couples in Trouble Relationship Expert, Dr. Jackie Black, Offers a Gift Guide to Reignite the Spark So Lovers Can Kiss-And-Make-Up 2Health News:Couples in Trouble Relationship Expert, Dr. Jackie Black, Offers a Gift Guide to Reignite the Spark So Lovers Can Kiss-And-Make-Up 3Health News:Loffler Companies Named Microsoft Community Connections Partner of the Year Award Winner 2Health News:Loffler Companies Named Microsoft Community Connections Partner of the Year Award Winner 3
    ... not to board a transatlantic flight with a potentially deadly ... and two Czechs who flew with him, media said ... scare two months ago when he flew to Montreal via ... Disease Control (CDC) had said he was infected with a ...
    ... operation for a rare birth defect has more than one share ... illegal immigrants in the U.S, have also been granted a ... daughter. ,Hazelle Roas little-known genetic abnormality left her with ... kept her in the hospital most of her life. According ...
    ... tattoo done of their lover's initials due to fear of ... - researchers have discovered a technique, where the cryptic body ... choice. ,The new method is called micro-encapsulation, where ... that are as tiny as pins, can bear a molecule ...
    ... of foods like white rice, pasta and bread, which ... macular degeneration (AMD). ,However, whole-wheat versions of ... have a low-glycemic-index. These foods are often considered higher ... and less dramatic rise and fall of blood sugar. ...
    ... turned nasty for a group of around ten ... , A Srilankan group of students who visited ... picnic organized by the Punqudutivu Students Association of Sri Lanka ... and abdominal cramps.,Toronto Public Health on Thursday confirmed six cases ...
    ... cash in on the Dutch laws. ,The former American ... cookie while touring in the Netherlands. ,"It was ... legal here. I don't ever do anything illegal here, People ... 25-year-old singer said that the cookie was an experiment and ...
    Cached Medicine News:Health News:US TB Traveler Sued Over 'reckless and Selfish Behavior' 2Health News:Too Much White Rice, Pasta and Bread may Increase Chances of AMD 2Health News:Too Much White Rice, Pasta and Bread may Increase Chances of AMD 3
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    Medicine Products: